Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.59USD
−35.47 MUSD
0.00USD
75.82 M
About ProKidney Corp.
Sector
Industry
CEO
Bruce Culleton
Website
Headquarters
Winston-Salem
Founded
2015
FIGI
BBG0119BQ2Y2
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PROK is 1.72 USD — it has increased by 2.29% in the past 24 hours. Watch ProKidney Corp. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ProKidney Corp. stocks are traded under the ticker PROK.
PROK stock has fallen by −6.77% compared to the previous week, the month change is a −10.50% fall, over the last year ProKidney Corp. has showed a 14.67% increase.
We've gathered analysts' opinions on ProKidney Corp. future price: according to them, PROK price has a max estimate of 6.00 USD and a min estimate of 3.00 USD. Watch PROK chart and read a more detailed ProKidney Corp. stock forecast: see what analysts think of ProKidney Corp. and suggest that you do with its stocks.
PROK reached its all-time high on Mar 13, 2023 with the price of 14.19 USD, and its all-time low was 1.12 USD and was reached on Nov 17, 2023. View more price dynamics on PROK chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PROK stock is 7.19% volatile and has beta coefficient of 0.80. Track ProKidney Corp. stock price on the chart and check out the list of the most volatile stocks — is ProKidney Corp. there?
Today ProKidney Corp. has the market capitalization of 225.63 M, it has increased by 12.57% over the last week.
Yes, you can track ProKidney Corp. financials in yearly and quarterly reports right on TradingView.
ProKidney Corp. is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
PROK earnings for the last quarter are −0.16 USD per share, whereas the estimation was −0.25 USD resulting in a 36.75% surprise. The estimated earnings for the next quarter are −0.13 USD per share. See more details about ProKidney Corp. earnings.
ProKidney Corp. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
PROK net income for the last quarter is −12.51 M USD, while the quarter before that showed −9.49 M USD of net income which accounts for −31.75% change. Track more ProKidney Corp. financial stats to get the full picture.
No, PROK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 30, 2024, the company has 163.00 employees. See our rating of the largest employees — is ProKidney Corp. on this list?
Like other stocks, PROK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ProKidney Corp. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ProKidney Corp. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ProKidney Corp. stock shows the strong sell signal. See more of ProKidney Corp. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.